Arena Pharmaceuticals (Arena Pharmaceuticals) EV-to-EBIT : -9.02 (As of May. 05, 2024)

Arena Pharmaceuticals EV-to-EBIT Chart

Arena Pharmaceuticals Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBIT		Get a 7-Day Free Trial					-14.36	-11.51	3.10	-8.61	-8.51

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
EV-to-EBIT	Get a 7-Day Free Trial															-8.61	-7.30	-6.54	-4.92	-8.51

Competitive Comparison of Arena Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Arena Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arena Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's EV-to-EBIT falls into.

Arena Pharmaceuticals EV-to-EBIT Calculation

Arena Pharmaceuticals's EV-to-EBIT for today is calculated as:

Arena Pharmaceuticals's current Enterprise Value is $5,656.06 Mil.
Arena Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-626.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arena Pharmaceuticals  (NAS:ARNA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Arena Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

Arena Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2021 was $5,212.51 Mil.
Arena Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-626.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arena Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description